Interleukin-5 levels in relation to malaria severity: a systematic review.
Complicated
Cytokine
IL-5
Interleukin
Malaria
Severe
Uncomplicated
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
03 Aug 2023
03 Aug 2023
Historique:
received:
15
01
2023
accepted:
25
07
2023
medline:
7
8
2023
pubmed:
4
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
The role of cytokines such as interleukin-5 (IL-5) in the pathogenesis of malaria remains unclear. This systematic review sought to synthesize variations in IL-5 levels between severe and uncomplicated malaria, as well as between malaria and controls not afflicted with the disease. This systematic review was registered at the International Prospective Register of Systematic Reviews (PROSPERO; CRD42022368773). Searches for studies that reported IL-5 levels in patients with malaria (any severity) and/or uninfected individuals were performed in Web of Science, PubMed, EMBASE, Scopus, CENTRAL, and MEDLINE, between 1st and 10th October, 2022. The risk of bias among all included studies was minimized using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for reporting observational studies. The differences in IL-5 levels between malaria and uninfected controls, and between severe and uncomplicated malaria were synthesized by narrative synthesis. Among 1177 articles identified in the databases, 23 matched the eligibility criteria and were included in this systematic review. Qualitative syntheses showed the heterogeneity of IL-5 levels between different severities of clinical malaria and uninfected controls. The majority of the included studies (12/15 studies, 80%) found no change in IL-5 levels between malaria cases and uninfected controls. Similarly, most studies found no difference in IL-5 levels between severe (regardless of complications) and uncomplicated malaria (4/8 studies, 50%). The qualitative syntheses revealed that most studies found no difference in IL-5 levels between severe and non-severe malaria. The comprehensive review suggests that IL-5 levels are unchanged in patients with different levels of clinical severity of malaria and uninfected controls. Given the limited number of published studies on IL-5 levels in malaria, there is a need for additional research to determine the function of this cytokine in the pathogenesis of malaria.
Sections du résumé
BACKGROUND
BACKGROUND
The role of cytokines such as interleukin-5 (IL-5) in the pathogenesis of malaria remains unclear. This systematic review sought to synthesize variations in IL-5 levels between severe and uncomplicated malaria, as well as between malaria and controls not afflicted with the disease.
METHODS
METHODS
This systematic review was registered at the International Prospective Register of Systematic Reviews (PROSPERO; CRD42022368773). Searches for studies that reported IL-5 levels in patients with malaria (any severity) and/or uninfected individuals were performed in Web of Science, PubMed, EMBASE, Scopus, CENTRAL, and MEDLINE, between 1st and 10th October, 2022. The risk of bias among all included studies was minimized using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for reporting observational studies. The differences in IL-5 levels between malaria and uninfected controls, and between severe and uncomplicated malaria were synthesized by narrative synthesis.
RESULTS
RESULTS
Among 1177 articles identified in the databases, 23 matched the eligibility criteria and were included in this systematic review. Qualitative syntheses showed the heterogeneity of IL-5 levels between different severities of clinical malaria and uninfected controls. The majority of the included studies (12/15 studies, 80%) found no change in IL-5 levels between malaria cases and uninfected controls. Similarly, most studies found no difference in IL-5 levels between severe (regardless of complications) and uncomplicated malaria (4/8 studies, 50%). The qualitative syntheses revealed that most studies found no difference in IL-5 levels between severe and non-severe malaria.
CONCLUSIONS
CONCLUSIONS
The comprehensive review suggests that IL-5 levels are unchanged in patients with different levels of clinical severity of malaria and uninfected controls. Given the limited number of published studies on IL-5 levels in malaria, there is a need for additional research to determine the function of this cytokine in the pathogenesis of malaria.
Identifiants
pubmed: 37537570
doi: 10.1186/s12936-023-04659-3
pii: 10.1186/s12936-023-04659-3
pmc: PMC10401852
doi:
Substances chimiques
Cytokines
0
Interleukin-5
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
226Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Infect Immun. 2020 Jul 21;88(8):
pubmed: 32513854
J Immunol Methods. 2008 Feb 29;331(1-2):59-68
pubmed: 18089291
Malar J. 2008 May 19;7:83
pubmed: 18489763
PLoS One. 2019 Apr 19;14(4):e0215550
pubmed: 31002731
Malar J. 2022 Jul 12;21(1):217
pubmed: 35820892
ACS Sens. 2020 Jun 26;5(6):1506-1513
pubmed: 32482077
Trop Med Infect Dis. 2022 Oct 13;7(10):
pubmed: 36288040
Int J Environ Res Public Health. 2022 Jul 30;19(15):
pubmed: 35954703
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
PLoS One. 2013 Oct 10;8(10):e77214
pubmed: 24130857
Front Cell Infect Microbiol. 2022 Jun 23;12:901433
pubmed: 35811678
Int Immunol. 1996 Feb;8(2):237-45
pubmed: 8671609
J Infect Dis. 2006 Jul 15;194(2):198-207
pubmed: 16779726
Infect Immun. 2006 Oct;74(10):5718-24
pubmed: 16988248
View (Beijing). 2021 Aug;2(4):20210003
pubmed: 34766163
J Travel Med. 2022 Jul 14;29(4):
pubmed: 35467747
PLoS One. 2020 Jun 19;15(6):e0235014
pubmed: 32559238
Infect Dis Obstet Gynecol. 2010;2010:
pubmed: 20706538
Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(8):463-85
pubmed: 21986312
PLoS Negl Trop Dis. 2020 May 4;14(5):e0008155
pubmed: 32365058
J Infect Dis. 2015 Feb 1;211(3):436-44
pubmed: 25139023
Cytokine. 2000 Sep;12(9):1299-306
pubmed: 10975987
JDS Commun. 2022 Mar 03;3(3):207-211
pubmed: 36338808
Sci Rep. 2022 Nov 7;12(1):18917
pubmed: 36344583
Parasit Vectors. 2022 Aug 6;15(1):285
pubmed: 35933389
Infect Dis Poverty. 2020 Jul 29;9(1):106
pubmed: 32727617
Adv Immunol. 2009;101:191-236
pubmed: 19231596
Travel Med Infect Dis. 2008 Jan-Mar;6(1-2):67-81
pubmed: 18342278
Malar J. 2015 Aug 14;14:315
pubmed: 26271921
Blood. 1998 Apr 1;91(7):2264-71
pubmed: 9516124
J Transl Med. 2015 Nov 24;13:369
pubmed: 26602091
Infect Immun. 2014 Sep;82(9):3783-9
pubmed: 24958713
PLoS One. 2018 Jan 2;13(1):e0189958
pubmed: 29293589
Malar J. 2020 Jul 31;19(1):274
pubmed: 32736635
J Immunol Res. 2014;2014:318250
pubmed: 24741587
Malar J. 2022 Oct 29;21(1):308
pubmed: 36309676
Front Med (Lausanne). 2018 Apr 06;5:49
pubmed: 29682504
Infect Immun. 2011 Nov;79(11):4674-80
pubmed: 21859849
Am J Hematol. 2012 Jul;87(7):652-8
pubmed: 22570198
Mediators Inflamm. 2016;2016:4286576
pubmed: 27418744
Malar J. 2006 Oct 10;5:85
pubmed: 17029647
Sci Rep. 2022 Apr 8;12(1):5982
pubmed: 35396564
Clin Vaccine Immunol. 2017 Apr 5;24(4):
pubmed: 28122790
BMC Infect Dis. 2020 May 24;20(1):363
pubmed: 32448216
Mol Cell Biol. 1994 Nov;14(11):7404-13
pubmed: 7935454
Malar J. 2007 Nov 12;6:147
pubmed: 17997848
PLoS One. 2013 Aug 14;8(8):e73360
pubmed: 23967342
Cytokine X. 2019 Oct 04;1(4):100014
pubmed: 33604551